Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Arrowhead Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get ARWR alerts

About Chris Anzalone

Chris Anzalone is recorded as CEO at Arrowhead Pharmaceuticals, Inc. (ARWR). Chris Anzalone has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Arrowhead Pharmaceuticals, Inc. on September 15, 2026. Arrowhead Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arrowhead Pharmaceuticals, Inc. includes Christopher Anzalone (CEO and Board Member), Daniel Apel (CFO), Patrick O'Brien (COO) and 7 others.

Chris Anzalone on recent calls

“It's really a pleasure to join you today. So the Aerodyner PA, I think, was a breakthrough for us and I think for the field for a couple You know, one, broadly, you know, this is the first time anybody has shown knockdown of two genes, you know, with a single molecule using RNAi.”
CEO, Morgan Stanley 24th Annual Global Healthcare Conference ·
“Earlier today, we announced that the license and collaboration agreement with Sarepta Therapeutics is closed. Arrowhead expects to receive a $500 million upfront payment in the next 10 days and has already received $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.”
CEO, Arrowhead Pharmaceuticals, Inc. Q1 FY2025 Earnings Call ·
“Over the years, we've built platforms capable of addressing liver, lung, adipose, CNS, skeletal muscle, cardiomyocyte, and soon other cell types to bring RNAi therapeutics to where a multitude of diseases are.”
CEO, Arrowhead Pharmaceuticals, Inc. Q4 FY2024 Earnings Call ·
“Arrowhead has spent a substantial amount of time building a scalable platform on which a large number of diverse and innovative new medicines have been and will continue to be built.”
CEO, Arrowhead Pharmaceuticals, Inc. Q3 FY2024 Earnings Call ·
“Arrowhead has made a name for itself as a company capable of rapid innovation and development that is building a broad-based diverse business.”
CEO, Arrowhead Pharmaceuticals, Inc. Q1 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Arrowhead Pharmaceuticals, Inc.

Recent activity